Breast Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Pancreatic Neoplasm, Renal Neoplasm
Conditions
Keywords
Gene, HER2, Clinical Trial, Phase I, Breast neoplasm, Pancreatic neoplasm, Ovarian neoplasm, Colorectal neoplasm, Renal neoplasm, Prostate neoplasm, Cancer
Brief summary
The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
Detailed description
The human epidermal growth factor receptor 2 (HER2) is a member of the Type 1 family of growth factor tyrosine kinases. HER2 forms hetero- and homo-dimers with other members of this family of tyrosine kinases. As a result of dimerization at the cell surface, intracellular signal transduction is initiated, resulting in cell proliferation. HER2 expression has been observed in a variety of human tumors including breast cancer, non-small cell lung cancer, prostate cancer, pancreatic cancer, renal cell cancer, and ovarian cancer. HER2 overexpression is associated with clinically more aggressive breast cancer, and is an independent predictor of poor prognosis in patients with breast cancer. TAK-165 is an active and selective inhibitor of tyrosine kinase activity of HER2 being developed for patients with lower levels of HER2 expression. This study will seek to determine the safety, tolerability, maximum tolerated dose and pharmacokinetics of TAK-165 administered to subjects with tumors known to express HER2. The total duration of the study will be at minimum 8 weeks, or 56 Days. Subjects without progressive disease after 8 weeks may continue to receive study drug, provided that they do not meet criteria for withdrawal.
Interventions
DRUGTAK-165
Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
Sponsors
Takeda
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have advanced or metastatic cancer which is refractory to standard therapy or subjects for whom there is no known effective therapy. * Have a histologically or cytologically proven diagnosis of a solid tumor known to express HER2. * Have a predicted life expectancy of greater than or equal to 12 weeks. * Have a Karnofsky Performance Status of greater than or equal to 60% * Have recovered from toxicities of prior chemotherapy, surgery, or radiotherapy.
Exclusion criteria
* Be pregnant or lactating. Women of childbearing potential must have a negative serum pregnancy test result within 7 days of enrollment into the study. Male and female subjects of childbearing potential (including women who have been amenorrheic for less than 1 year) must use appropriate birth control during the entire duration of the study, or the subject must be surgically sterile. * Have symptomatic brain metastasis * Have received any other anti-cancer treatment or investigational drug/treatment within 28 days prior to study Day 1. * Have a history of another malignancy within the last 5 years. * Have inadequate organ function. * Have heart failure defined by an ejection fraction of less than or equal to 50% as measured by MUGA. * Have Class II, III or IV symptoms of heart failure as defined by the New York Heart Association, or uncontrolled arrhythmias, or recent history of myocardial infarction or angina pectoris. * Have a medical condition that may interfere with intake and/or absorption of the study drug (e.g., gastrectomy or resection of major portion of small intestine). * Have any other serious disease or condition present at screening or at study Day 1 that might affect life expectancy or make it difficult to successfully manage and follow the subject according to the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose Limiting Toxicity | Days 8, 15, 22, 28 and every 14 days thereafter to Final Visit |
| Maximum Tolerated Dose | Days 8, 15, 22, 28 and every 14 days thereafter to Final Visit |
| Optimal Dosing for Phase II Studies. | End of Study. |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Pharmacokinetic Profile of TAK-165 | Days 8, 15, 22, 28 and every 14 days thereafter to Final Visit |
| Response Evaluation Criteria in Solid Tumors Documentation of Objective Tumor Response. | Day 56 |
Countries
United States
Outcome results
None listed